Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

Inclusion Criteria: * Definition of cachexia (see Section 11.1) fulfilled * Age ≥ 18 years * Confirmed tumor of any site * Life expectancy of ≥3 months * Subject must be willing to receive transfusion of blood products * Patient must give written informed consent * Females of childbearing potential (FCBP) must undergo pregnancy testing (serum) and pregnancy result must be negative.\* * Reliable contraception should be maintained throughout the study and for 28 days after study treatment discontinuation * Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods * Males (including those who have had a vasectomy) must use barrier contraception (condoms) when engaging in sexual activity with FCBP. Males must agree not to donate semen or sperm Exclusion Criteria: * Pregnant or breast feeding females * Lack of written informed consent * No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician about study participation. * No consent for "Translational Research" and "Biobanking" (see separate documents "Aufbewahrung und Weiterverwendung von biologischem Material und von Daten für die biomedizinische Forschung" und "Biobankreglement" for the RUXexia Trial). * Thrombocytopenia \< 50 x 10e9/l * Peroral intake not possible, in particular by stenosis of the esophagus * New started treatment of the tumor (first 3…